Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted December 8, 2017
Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns
On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung condition called hypersensitivity pneumonitis. The FDA recommended Primus Pharmaceuticals recall Limbrel, but the company has not recalled the product at this time.